Your browser doesn't support javascript.
loading
BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression.
Xing, Lijie; Wang, Su; Liu, Jiye; Yu, Tengteng; Chen, Hailin; Wen, Kenneth; Li, Yuyin; Lin, Liang; Hsieh, Phillip A; Cho, Shih-Feng; An, Gang; Qiu, Lugui; Kinneer, Krista; Munshi, Nikhil; Anderson, Kenneth C; Tai, Yu-Tzu.
Afiliación
  • Xing L; Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston Massachusetts.
  • Wang S; Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China.
  • Liu J; Department of Biomedical Informatics, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts.
  • Yu T; Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston Massachusetts.
  • Chen H; Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston Massachusetts.
  • Wen K; Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston Massachusetts.
  • Li Y; Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston Massachusetts.
  • Lin L; Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston Massachusetts.
  • Hsieh PA; School of Food Engineering and Biotechnology, Tianjin University of Science and Technology, Tianjin, China.
  • Cho SF; Key Lab of Industrial Fermentation Microbiology of the Ministry of Education.
  • An G; State Key Laboratory of Food Nutrition and Safety, Tianjin University of Science and Technology, Tianjin China.
  • Qiu L; Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston Massachusetts.
  • Kinneer K; Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston Massachusetts.
  • Munshi N; Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston Massachusetts.
  • Anderson KC; Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Tai YT; School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Clin Cancer Res ; 27(19): 5376-5388, 2021 10 01.
Article en En | MEDLINE | ID: mdl-34301753
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inmunoconjugados / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inmunoconjugados / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article